Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
60S ribosomal protein L27a (RPL27A) is a structural protein component of the large 60S ribosomal subunit in eukaryotic cells[1][3][5]. It belongs to the L15P family of ribosomal proteins and plays an essential role in protein synthesis as part of the ribosome complex, facilitating peptide chain elongation[1][3]. RPL27A is expressed in the cytoplasm and is required for cellular growth and protein translation. Altered expression of this gene has been observed in colorectal cancer tissues, though there is no established correlation with disease progression[1][3]. Mutations in RPL27A are also implicated in some rare inherited diseases, such as congenital disorders of glycosylation and cone-rod dystrophy[3]. There is currently no evidence that RPL27A serves as a direct therapeutic target, interacts with any approved drugs, or acts as a biomarker in clinical settings[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 60S ribosomal protein L27a (RPL27A).